Search
Gatifloxacin
go.drugbank.com/drugs/DB01044ApprovedInvestigationalWithdrawnGatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. … It is also available as eye drops under the brand name Zymar® marketed by Allergan.
Cefaclor
go.drugbank.com/drugs/DB00833ApprovedInvestigationalSemisynthetic, broad-spectrum antibiotic derivative of cephalexin.
Estradiol dienanthate
go.drugbank.com/drugs/DB13955ApprovedVet approvedWithdrawnEstradiol dienanthate is not currently available in any commercially available products in Canada or the US. … First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102].
Lactitol
go.drugbank.com/drugs/DB12942Approved[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.[L11803] … [A190912] Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in
Delandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigationalDelandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy developed by Sarepta Therapeutics. … [L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein.
Suramin
go.drugbank.com/drugs/DB04786InvestigationalSuramin is manufactured by Bayer in Germany as Germanin®. … A polyanionic compound with an unknown mechanism of action.
Saredutant
go.drugbank.com/drugs/DB06660InvestigationalSaredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
TrenibotulinumtoxinE
go.drugbank.com/drugs/DB19082Approved[L64095] TrenibotulinumtoxinE was approved by Health Canada in June 2026[L64128] and by the European Commission on July 17, 2026, with the decision applying across all 30 European Economic Area countries … [L64095,L64118] It is given as an intramuscular injection into the corrugator and procerus muscles, is intended for occasional use, and its potency units are not interchangeable with those of other botulinum
Tigecycline
go.drugbank.com/drugs/DB00560ApprovedInvestigationalTigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. … It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.